DENTSPLY SIRONA (NASDAQ:XRAY) Director Brian Mckeon Acquires 10,000 Shares

DENTSPLY SIRONA Inc. (NASDAQ:XRAY) Director Brian Mckeon bought 10,000 shares of the business’s stock in a transaction on Friday, June 12th. The stock was acquired at an average cost of $10.12 per share, for a total transaction of $101,200.00. Following the acquisition, the director directly owned 10,000 shares of the company’s stock, valued at $101,200. The trade was a ? increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink.

DENTSPLY SIRONA Stock Up 0.5%

NASDAQ:XRAY opened at $10.14 on Tuesday. The company has a current ratio of 1.53, a quick ratio of 0.98 and a debt-to-equity ratio of 1.52. The stock has a 50 day moving average of $10.95 and a 200-day moving average of $11.71. The firm has a market capitalization of $2.03 billion, a PE ratio of -3.22, a price-to-earnings-growth ratio of 1.20 and a beta of 0.89. DENTSPLY SIRONA Inc. has a 52 week low of $9.40 and a 52 week high of $17.09.

DENTSPLY SIRONA (NASDAQ:XRAY) last announced its quarterly earnings results on Tuesday, May 5th. The medical instruments supplier reported $0.27 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.28 by ($0.01). The company had revenue of $880.00 million during the quarter, compared to the consensus estimate of $841.80 million. DENTSPLY SIRONA had a positive return on equity of 18.83% and a negative net margin of 17.06%.The company’s revenue for the quarter was up .1% on a year-over-year basis. During the same period last year, the business posted $0.43 EPS. DENTSPLY SIRONA has set its FY 2026 guidance at 1.400-1.500 EPS. Analysts predict that DENTSPLY SIRONA Inc. will post 1.42 EPS for the current year.

Analyst Ratings Changes

XRAY has been the subject of several recent research reports. Mizuho lowered their price target on shares of DENTSPLY SIRONA from $16.00 to $14.00 and set a “neutral” rating for the company in a research report on Wednesday, May 6th. Zacks Research raised shares of DENTSPLY SIRONA from a “strong sell” rating to a “hold” rating in a research note on Monday, March 2nd. Wells Fargo & Company raised their price target on shares of DENTSPLY SIRONA from $12.00 to $13.00 and gave the company an “equal weight” rating in a research note on Friday, February 27th. Bank of America raised DENTSPLY SIRONA from a “neutral” rating to a “buy” rating and lifted their price target for the company from $13.00 to $17.00 in a report on Thursday, February 19th. Finally, Barrington Research boosted their price objective on DENTSPLY SIRONA from $14.00 to $17.00 and gave the stock an “outperform” rating in a research report on Monday, March 2nd. Three equities research analysts have rated the stock with a Buy rating, eight have assigned a Hold rating and three have assigned a Sell rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Hold” and a consensus price target of $13.55.

Institutional Trading of DENTSPLY SIRONA

A number of hedge funds and other institutional investors have recently made changes to their positions in XRAY. Southpoint Capital Advisors LP bought a new stake in DENTSPLY SIRONA during the first quarter worth approximately $116,000,000. AQR Capital Management LLC increased its holdings in shares of DENTSPLY SIRONA by 109.8% in the second quarter. AQR Capital Management LLC now owns 13,316,771 shares of the medical instruments supplier’s stock valued at $211,470,000 after buying an additional 6,970,086 shares in the last quarter. Armistice Capital LLC lifted its position in shares of DENTSPLY SIRONA by 1,044.0% during the 3rd quarter. Armistice Capital LLC now owns 5,736,000 shares of the medical instruments supplier’s stock valued at $72,790,000 after acquiring an additional 5,234,587 shares during the last quarter. Jacobs Levy Equity Management Inc. lifted its position in shares of DENTSPLY SIRONA by 662.0% during the 3rd quarter. Jacobs Levy Equity Management Inc. now owns 4,608,341 shares of the medical instruments supplier’s stock valued at $58,480,000 after acquiring an additional 4,003,606 shares during the last quarter. Finally, Goldman Sachs Group Inc. boosted its stake in shares of DENTSPLY SIRONA by 827.3% during the 1st quarter. Goldman Sachs Group Inc. now owns 2,434,925 shares of the medical instruments supplier’s stock worth $36,378,000 after acquiring an additional 2,172,343 shares in the last quarter. 95.70% of the stock is currently owned by institutional investors.

DENTSPLY SIRONA Company Profile

Dentsply Sirona Inc (NASDAQ: XRAY) is a leading global manufacturer of professional dental products and technologies. The company, formed through the merger of Dentsply International and Sirona Dental Systems in February 2016, brings together a long heritage of innovation in dental care. Headquartered in Charlotte, North Carolina, Dentsply Sirona develops and markets a comprehensive range of dental consumables, laboratory products, and advanced imaging and CAD/CAM systems.

The company’s product portfolio spans preventive, restorative, orthodontic, endodontic and surgical care.